Global Contract Dose Manufacturing Market Size By Type (Solid Dosage Form, Liquid Dosage Form), By Application (Pharmaceutical Companies, Biopharmaceutical Companies), By Region, And Segment Forecasts...

The Global Contract Dose Manufacturing Market was valued at USD 95.3 billion in 2023 and is expected to reach USD 165.7 billion by 2031, growing at a CAGR of 7.1% during the forecast period (2023–2031). This market is witnessing robust expansion driven by the increasing demand for pharmaceutical outsourcing, rising R&D costs, and the growing need for cost-efficient production processes. Contract dose manufacturers offer essential capabilities such as formulation development, clinical trial material manufacturing, and large-scale commercial production—particularly beneficial for small and mid-sized pharmaceutical firms lacking in-house infrastructure.

Drivers:

1. Surge in Outsourcing Activities by Pharmaceutical Companies:

The increasing complexity and cost of drug development are encouraging pharma companies to outsource dose manufacturing to specialized contract manufacturers to improve operational efficiency and accelerate time to market.

2. Expansion of Biologics and Specialty Drugs:

Growing demand for biologics, personalized medicine, and complex therapies necessitates specialized manufacturing capabilities, which contract manufacturers are well-equipped to offer.

3. Regulatory Support for Outsourcing:

Favorable regulatory frameworks supporting the outsourcing of drug development and manufacturing activities are propelling the growth of the global contract dose manufacturing market.

Restraints:

1. Intellectual Property (IP) Concerns:

Pharmaceutical companies are often hesitant to share proprietary information with third parties due to potential risks of IP theft or breach.

2. Variability in Quality Standards:

Differences in manufacturing standards and regulatory compliance across geographies can pose quality control issues and regulatory delays.

Opportunity:

1. Growing Demand from Emerging Markets:

Pharmaceutical demand is rising sharply in Asia-Pacific and Latin America, opening new avenues for contract manufacturers to expand geographically and offer scalable production at competitive costs.

2. Increasing Investment in Oral Solid Dosage (OSD) and Injectable Forms:

Investments in advanced manufacturing technologies for tablets, capsules, and sterile injectables are unlocking high-value opportunities, particularly in oncology and chronic disease segments.

Market by System Type Insights:

By system type, oral solid dosage (OSD) remains the leading segment, accounting for the largest share in 2023. Tablets and capsules are preferred for their convenience, cost-effectiveness, and patient compliance. However, the injectables segment is forecasted to register the fastest growth rate due to increasing biologics approvals and demand for parenteral delivery methods.

Market by End-Use Insights:

The pharmaceutical companies segment held the largest market share in 2023, owing to their widespread reliance on contract dose manufacturers to streamline costs and improve focus on core competencies like R&D and marketing. Meanwhile, the biotechnology firms segment is expected to witness substantial growth due to increasing innovation in biologics and cell & gene therapy domains.

Market by Regional Insights:

North America dominated the contract dose manufacturing market in 2023, led by strong outsourcing trends, presence of leading CDMOs, and high pharmaceutical R&D expenditure. However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period, driven by cost-efficient manufacturing hubs in India and China and favorable government policies to attract global pharmaceutical players.

Competitive Scenario:

Key players in the Global Contract Dose Manufacturing Market include Catalent Inc., Lonza Group, Recipharm AB, Thermo Fisher Scientific Inc., Jubilant Pharmova, Patheon, Piramal Pharma Solutions, Siegfried Holding AG, Almac Group, and Samsung Biologics. These companies are actively pursuing capacity expansions, strategic alliances, and advanced manufacturing technologies to bolster their market presence.

Recent Developments:

In 2024, Catalent expanded its biologics manufacturing capacity with a new high-speed vial filling line in Belgium.

In 2023, Lonza partnered with a major biopharma firm to support the commercial supply of a next-gen monoclonal antibody therapy.

In 2022, Recipharm acquired a state-of-the-art OSD facility in the U.S. to strengthen its North American footprint.

Scope of Work – Global Contract Dose Manufacturing Market

Key Market Developments:

April 2024: Thermo Fisher Scientific announced a $300 million investment to expand its sterile drug manufacturing capabilities in the U.S.

January 2024: Jubilant Pharmova signed a long-term supply agreement with a global specialty pharma company for oncology drug production.

October 2023: Piramal Pharma Solutions launched a new continuous manufacturing platform for oral dosage forms.

FAQs:

1) What is the current market size of the Global Contract Dose Manufacturing Market?

The market was valued at USD 95.3 billion in 2023.

2) What is the major growth driver of the Global Contract Dose Manufacturing Market?

The primary driver is the increasing outsourcing of pharmaceutical dose manufacturing to optimize costs and focus on core R&D.

3) Which is the largest region during the forecast period in the Global Contract Dose Manufacturing Market?

North America led the market in 2023; however, Asia-Pacific is expected to witness the fastest growth during the forecast period.

4) Which segment accounted for the largest market share in Global Contract Dose Manufacturing Market?

The Oral Solid Dosage (OSD) segment held the largest share in 2023.

5) Who are the key market players in the Global Contract Dose Manufacturing Market?

Major players include Catalent Inc., Lonza Group, Thermo Fisher Scientific, Recipharm AB, Jubilant Pharmova, and Piramal Pharma Solutions.